Date: 2015-04-27
Type of information: Financing round
Company: Pep Therapy (France)
Investors: Seventure Partners (France) Bernard Majoie (France)
Amount: €1.3 million
Funding type: financing round
Planned used: These funds will enable PEP-Therapy to undertake regulatory development of its first therapeutic product, associated with a predictive biomarker for foreseeing the effectiveness of the treatment. The product relies on the innovative technology of bi-functional peptides, which penetrate cells and then specifically block pathological mechanisms, without affecting normal physiological mechanisms.This cell-penetrating and interfering peptide (CP&IP) technology has been developed at Université Pierre et Marie Curie, Inserm and Institut Curie, Paris.
Others: * On April 27, 2015, PEP Therapy announced that the company has raised €1.3 million in initial funding. These funds were provided by the Quadrivium 1 seed fund, managed by Seventure Partners, for €1 million, supplemented by a personal investment of €300,000 from Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l'Innovation (FFMI).
Therapeutic area: Cancer - Oncology
